These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7085383)

  • 1. Evaluation of the bioavailability of misonidazole (NSC#261037) in capsule and tablet form and pharmacologic effects of daily dosage.
    VanRaalte G; Phillips TL; Wasserman TH
    Int J Radiat Oncol Biol Phys; 1982 Feb; 8(2):279-82. PubMed ID: 7085383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetic aspects of misonidazole and its major metabolite in radiotherapy.
    Meering PG; Gonzalez DG; Maes RA; van Peperzeel HA
    Hum Toxicol; 1985 Jul; 4(4):425-34. PubMed ID: 4018823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics of misonidazole in the dog.
    White RA; Workman P; Freedman LS; Owen LN; Bleehen NM
    Eur J Cancer (1965); 1979 Oct; 15(10):1233-42. PubMed ID: 520395
    [No Abstract]   [Full Text] [Related]  

  • 4. Phenytoin-misonidazole: possible metabolic interaction.
    Gangji D; Schwade JG; Strong JM
    Cancer Treat Rep; 1980 Jan; 64(1):155-6. PubMed ID: 7379050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Final report on the United States Phase I Clinical Trial of the hypoxic cell radiosensitizer, misonidazole (Ro-07-0582; NSC #261037).
    Phillips TL; Wasserman TH; Johnson RJ; Levin VA; VanRaalte G
    Cancer; 1981 Oct; 48(8):1697-704. PubMed ID: 6269723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desmethylmisonidazole (Ro 05-9963): clinical pharmacokinetics after multiple oral administration.
    Stratford MR; Minchinton AI; Dische S; Saunders MI; Anderson P
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):377-9. PubMed ID: 7107355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial United States clinical and pharmacologic evaluation of misonidazole (Ro-07-0582), an hypoxic cell radiosensitizer.
    Wasserman TH; Phillips TL; Johnson RJ; Gomer CJ; Lawrence GA; Sadee W; Marques RA; Levin VA; VanRaalte G
    Int J Radiat Oncol Biol Phys; 1979 Jun; 5(6):775-86. PubMed ID: 227821
    [No Abstract]   [Full Text] [Related]  

  • 8. Kinetics of misonidazole enantiomers.
    Williams KM
    Clin Pharmacol Ther; 1984 Dec; 36(6):817-23. PubMed ID: 6499361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Misonidazole dose and tumor level relationships. Effects of individual variation in rate of misonidazole metabolism and absorption from the gastrointestinal tract.
    Strong JM; Schwade JG; Gangji D; Shoemaker DD; Upton DK
    Cancer Clin Trials; 1981; 4(1):41-6. PubMed ID: 7214661
    [No Abstract]   [Full Text] [Related]  

  • 10. Steady-state bioavailability of two clorazepate dipotassium dosage forms.
    Carrigan PJ; Chao GC; Barker WM; Hoffman DJ; Chun AH
    J Clin Pharmacol; 1977 Jan; 17(1):18-28. PubMed ID: 13089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of local hyperthermia on the pharmacokinetics of misonidazole in the anaesthetized mouse.
    Honess DJ; Workman P; Morgan JE; Bleehen NM
    Br J Cancer; 1980 Apr; 41(4):529-40. PubMed ID: 7387851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetics and tumor and neural tissue penetrating properties of SR-2508 and SR-2555 in the dog--hydrophilic radiosensitizers potentially less toxic than misonidazole.
    White RA; Workman P; Brown JM
    Radiat Res; 1980 Dec; 84(3):542-61. PubMed ID: 6450431
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetic considerations of misonidazole in therapeutics.
    Matheson I; Plowman PN; Johnston A
    Hum Toxicol; 1984 Feb; 3(1):29-36. PubMed ID: 6698564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic, bladder wall, and bladder tumor concentration of misonidazole following intravesical administration in the rat.
    Fathi MA; Fisher GJ; Pageau R; Tahan TW; Nigam VN; Brailovsky CA; Elhilali MM
    Int J Radiat Oncol Biol Phys; 1983 Sep; 9(9):1397-400. PubMed ID: 6885552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-dependence and related studies on the pharmacokinetics of misonidazole and desmethylmisonidazole in mice.
    Workman P
    Cancer Chemother Pharmacol; 1980; 5(1):27-37. PubMed ID: 7460192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the bioavailability of digoxin in capsule, tablet, and solution taken orally with intravenous digoxin.
    Binnion PF
    J Clin Pharmacol; 1976 Oct; 16(10 Pt 1):461-7. PubMed ID: 977789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of the hypoxic radiosensitizers misonidazole and demethylmisonidazole after intraperitoneal administration in humans.
    Gianni L; Jenkins JF; Greene RF; Lichter AS; Myers CE; Collins JM
    Cancer Res; 1983 Feb; 43(2):913-6. PubMed ID: 6848201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of dexamethasone in the modification of misonidazole pharmacokinetics.
    Jones DH; Bleehen NM; Workman P; Walton MI
    Br J Cancer; 1983 Oct; 48(4):553-7. PubMed ID: 6626454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of microsomal enzyme inducers in the reduction of misonidazole neurotoxicity.
    Jones DH; Bleehen NM; Workman P; Smith NC
    Br J Radiol; 1983 Nov; 56(671):865-70. PubMed ID: 6626878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. I.V. misonidazole (NSC 261037). Report of initial clinical experience.
    Schwade JG; Strong JM; Gangji D
    Cancer Clin Trials; 1981; 4(1):33-9. PubMed ID: 7214660
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.